NCT06030180 (PR-0410) is a NA clinical trial of EsoGuard in Barrett Esophagus, sponsored by Lucid Diagnostics, Inc..

Who is sponsoring NCT06030180?

NCT06030180 is sponsored by Lucid Diagnostics, Inc..

What drugs are being tested in NCT06030180?

Interventions in NCT06030180: EsoGuard.

What condition does NCT06030180 study?

NCT06030180 studies Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophagus Adenocarcinoma.

Is NCT06030180 still recruiting?

NCT06030180 is currently completed. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT06030180: PR-0410

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CLUE: CLinical Utility Study of EsoGuard

Completed NA Last updated 27 June 2025

What this trial tests

NA trial testing EsoGuard in Barrett Esophagus in 566 participants. Completed in 13 December 2024.

Timeline

23 February 2023

Primary endpoint
13 December 2024

13 December 2024

Quick facts

Lead sponsor	Lucid Diagnostics, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	566
Start date	23 February 2023
Primary completion	13 December 2024
Estimated completion	13 December 2024
Sites	8 locations across United States

Drugs / interventions tested

EsoGuard

Conditions studied

Barrett Esophagus — all drugs for Barrett Esophagus →
Barretts Esophagus With Dysplasia — all drugs for Barretts Esophagus With Dysplasia →
Esophagus Adenocarcinoma — all drugs for Esophagus Adenocarcinoma →

Sponsor

Lucid Diagnostics, Inc.

Who can join

Adults 12 to 99, any sex, with Barrett Esophagus or Barretts Esophagus With Dysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Utilize real-world data from the commercial use of EsoGuard testing on samples collected with EsoCheck (EC/EG) to evaluate the impact of EsoGuard results on health care provider's decision for endoscopy referral. Assess patient compliance with recommendations for upper endoscopy, and relationship of compliance to positive EsoGuard results.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett's Esophagus (BE).
Lister D, Fine A, Maheshwari S, Bradley PS, et al · · 2024 · cited 2× · PMID 39768931 · DOI 10.3390/medicina60122052

Verify or expand the search:

Other trials of EsoGuard

Trials testing the same drug.

NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
NCT04293458 — Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE · NA · completed

Other recruiting trials for Barrett Esophagus

Currently open trials in the same condition.

NCT07126535 — Impact of RFA on Esophageal Distensibility and Mucosal Impedance · recruiting
NCT06746623 — Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux · NA · recruiting
NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
NCT06803147 — "Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillan · recruiting
NCT06693622 — Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests · recruiting

Other Lucid Diagnostics, Inc. trials

Trials by the same sponsor.

NCT05778851 — Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening fo · NA · completed
NCT05965999 — Lucid Registry Study · unknown
NCT04293458 — Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06030180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lucid Diagnostics, Inc.
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06030180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing